STOCKS TELEGRAPH

Tag: AVTE stock

  • Aerovate (AVTE) Shares Rally As Market Responds To A Merger Agreement

    Aerovate (AVTE) Shares Rally As Market Responds To A Merger Agreement

    The shares of Aerovate Therapeutics, Inc. (NASDAQ: AVTE) are on a notable uptick after the announcement of a merger agreement between the company and Jade Biosciences. On US stock charts, AVTE stock was up 18.49% at $2.60 at the time of the most recent market check.

    Merger Agreement Details

    The final merger agreement will be executed as an all-stock transaction, marking a significant milestone for both companies. The innovative portfolios of Aerovate (AVTE) and Jade Biosciences, a privately held biotechnology business dedicated to developing innovative therapies for autoimmune diseases, will be combined.

    There will be a lot of focus on JADE-001, a promising monoclonal antibody used to treat IgA nephropathy (IgAN). Upon completion of the deal, the new business will be known as Jade Biosciences and will trade on the Nasdaq under the ticker “JBIO.”

    Financial Backing and Future Operations

    To support this merger, Jade has successfully secured commitments for an oversubscribed private investment, projected to yield approximately $300 million from a consortium of healthcare investors. This financing will comprise common stock and pre-funded warrants, reflecting a strategic conversion of previously issued $95 million convertible notes.

    The merger’s financial structure is designed to ensure that the combined company will possess a cash balance sufficient to fund operations through 2027 and facilitate the advancement of JADE-001 towards initial clinical proof-of-concept.

    Ownership and Leadership Structure

    Upon the merger’s completion, pre-merger Aerovate stockholders will hold approximately 1.6% of the newly formed company, while pre-merger Jade stockholders, including those involved in the pre-closing financing, are expected to own about 98.4%. Notably, Aerovate plans to distribute a cash dividend of approximately $65 million to its stockholders immediately prior to the merger’s closure.

    Tom Frohlich, the current Chief Executive Officer of Jade, will lead the new entity, with the existing Board of Directors, chaired by Eric Dobmeier, retaining their positions. This merger represents a strategic path forward for Aerovate (AVTE), combining financial stability with Jade’s robust pipeline to create substantial value in the healthcare sector.

  • Aerovate Therapeutics, Inc. (AVTE) stock surged in the aftermarket – What’s making it rise?

    Aerovate Therapeutics, Inc. (AVTE) stock surged in the aftermarket – What’s making it rise?

    Aerovate Therapeutics, Inc. (AVTE) saw an increase of 5.17% in the aftermarket. However, the last trading session concluded at $14.13 with a decline of 18.65%.

    AVTE Announces Its Addition to the Russell 2000 Index

    On 17th September 2021, AVTE reported that it has been added to Russell 2000 Index. The Russell 2000 Index tracks the performance of small-cap stocks in the US stock market. Moreover, the Russell 3000 Index accounts for around 10% of the total market capitalization. The company tends to use Russell indexes as index funds and as benchmarks for active investment strategies by investment managers and institutional investors. Last but not least, Russell indexes are produced by FTSE Russell, one of the world’s top index providers.

    Second Quarter 2021 Financial Results

    AVTE announced second-quarter 2021 financial results on 16th August 2021. The cash and cash equivalents totaled $59.2 million, up from $4.6 million at the end of the previous fiscal year. Moreover, research and development (R&D) expenses were $4.3 million, up from $1.5 million in the second quarter of 2020. In the second quarter of 2021, compared to the second quarter of 2020, the increase in R&D spending was largely attributable to higher clinical trial and manufacturing costs.

    The general and administrative (G&A) expenses of AVTE were $1.4 million, compared to $0.2 million in the second quarter of 2020. The increase in G&A expenditures in the second quarter of 2021 compared to the second quarter of 2020 was largely attributable to higher legal, accounting, and consulting fees. Lastly, the net loss was $5.8 million, compared to $2.2 million in the same period in 2020. In the second quarter of 2021, stock-based compensation expenditure was $0.3 million, whereas, in the second quarter of 2020, it was $6,100.

    New Appointment to Board of Directors

    AVTE reported about the new appointment of Allison Dorval to the Board of Directors on 19th July 2021. Ms. Dorval is the finance director and primary finance and accounting officer of Voyager Therapeutics. Furthermore, she has over 20 years of experience in corporate finance, accounting, and operations, with 14 years in life sciences executive finance. Ms. Dorval formerly worked at Juniper Pharmaceuticals, Inc. as vice president of the controller. Lastly, she also worked at Insulet Corporation as a chief financial officer, where she oversaw personal finance, accounting, and auditing.